ArticleBMC medical imaging2025
Multimodal radiomics in glioma: predicting recurrence in the peritumoural brain zone using integrated MRI.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting early recurrence of craniopharyngioma using multi-omics radiomic modeling: a retrospective cohort study.Neurosurgical review · 2026Article
- Three-Dimensional quantitative analysis of the Peri-Enhancing zone reveals ADC and CBV signatures of glioblastoma recurrence.NeuroImage. Clinical · 2026Article
- Using Delta MRI-Based Radiomics for Monitoring Early Peri-Tumoral Changes in a Mouse Model of Glioblastoma: Primary Study.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGliomas exhibit a high recurrence rate, particularly in the peritumoural brain zone after surgery. This study aims to develop and validate a radiomics-based model using preoperative fluid-attenuated inversion recovery (FLAIR) and T1-weighted contrast-enhanced (T1-CE) magnetic resonance imaging (MRI) sequences to predict glioma recurrence within specific quadrants of the surgical margin.
methodsIn this retrospective study, 149 patients with confirmed glioma recurrence were included. 23 cases of data from Guizhou Medical University were used as a test set, and the remaining data were randomly used as a training set (70%) and a validation set (30%). Two radiologists from the research group established a Cartesian coordinate system centred on the tumour, based on FLAIR and T1-CE MRI sequences, dividing the tumour into four quadrants. Recurrence in each quadrant after surgery was assessed, categorising preoperative tumour quadrants as recurrent and non-recurrent. Following the division of tumours into quadrants and the removal of outliers, These quadrants were assigned to a training set (105 non-recurrence quadrants and 226 recurrence quadrants), a verification set (45 non-recurrence quadrants and 97 recurrence quadrants) and a test set (16 non-recurrence quadrants and 68 recurrence quadrants). Imaging features were extracted from preoperative sequences, and feature selection was performed using least absolute shrinkage and selection operator. Machine learning models included support vector machine, random forest, extra trees, and XGBoost. Clinical efficacy was evaluated through model calibration and decision curve analysis.
resultsThe fusion model, which combines features from FLAIR and T1-CE sequences, exhibited higher predictive accuracy than single-modality models. Among the models, the LightGBM model demonstrated the highest predictive accuracy, with an area under the curve of 0.906 in the training set, 0.832 in the validation set and 0.805 in the test set.
conclusionThe study highlights the potential of a multimodal radiomics approach for predicting glioma recurrence, with the fusion model serving as a robust tool for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.